Lupin Pharmaceuticals
Last updated Jun 18, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
68%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Antibiotic
Highest priority development: FDA AP — VYEPTI (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 68%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
3 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 18, 2026Score 16Lupin's Doxycycline ANDA204234 Receives AP Status from FDA
Infectious Disease · Antibiotic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — VYEPTI (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — ANDA219413Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — ANDA220639Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DOXYCYCLINE HYCLATE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Lupin Pharmaceuticals right now?
- Which regulatory precedents should Lupin Pharmaceuticals monitor in Infectious Disease and Antibiotic?
- How does Regulatory Developments in Antimalarial and Antibiotic Markets Signal Competitive Shifts compare to the nearest competitive programs?
- What signals require immediate investigation for Lupin Pharmaceuticals?
- Summarize the strategic implications of recent developments for Lupin Pharmaceuticals.
- Where is the greatest uncertainty in Lupin Pharmaceuticals's competitive positioning?